Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response by Pascal Demoly et al.
ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
Demoly et al. Allergy, Asthma & Clinical Immunology 2014, 10:29
http://www.aacijournal.com/content/10/1/29RESEARCH Open AccessReasons for prescribing second generation
antihistamines to treat allergic rhinitis in real-life
conditions and patient response
Pascal Demoly1*, Anca Mirela Chiriac1, Benoît Berge2 and Michel Rostin3Abstract
Background: Second generation H1 antihistamines (H1A) are currently recommended as first choice medications
for allergic rhinitis and rhinoconjunctivitis. However, little is known about what influences the choice of prescription
of one second generation (H1A) as opposed to another in real-life conditions.
Objective: The aim of the study was to identify the main criteria determining the choice of a second generation
H1A by allergy specialists in mainland France.
Methods: Consecutive patients suffering from allergic rhinitis or rhinoconjunctivitis were included and followed
prospectively for 30 days from the prescription of a second generation H1A in monotherapy. Patients were asked to
fill in auto-questionnaires at baseline, daily during the first 10 days of the new treatment, and at the end of
follow-up. Data on efficacy, tolerance, safety, rate and type of response to treatment, as well as patient satisfaction
were recorded and analyzed.
Results: 1,080 patients were included between March 2011 and October 2012, mostly suffering from moderate to
severe rhinitis (82.0%). The most frequently cited reason for choosing a specific H1A was the expected efficacy
(85.3%). The mean time to nasal and ocular recovery was 6 days and 78.2% of patients responded to treatment
within this interval. The presence of conjunctivitis was significantly associated with a more rapid response. At the
end of follow-up, the satisfaction rate was higher for patients who were switched from a previous treatment
(87.5%), compared to those receiving their first treatment (78.8%).
Conclusion and clinical relevance: The main reason for choosing a specific second generation H1A was its
expected efficacy. Concomitant conjunctivitis is associated with a more rapid response to treatment. Symptom
recovery necessitates a mean of 6 days.
Keywords: Allergic rhinitis, Quality of life, Second generation antihistamineIntroduction
Allergic rhinitis remains one of the most prevalent diseases
in Europe and constitutes an important health issue. In
France, prevalence was assessed at about 30% in an adult
population-based sample of more than 10,000 subjects [1].
Symptoms greatly impact general well-being and quality
of life of a significant proportion of patients, particularly
among those with persistent disease [2]. H1 antihistamine* Correspondence: pascal.demoly@inserm.fr
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unless otherwise stated.compounds (or H1A) are the main drugs prescribed to
prevent or alleviate nasal and ocular symptoms of al-
lergic rhinitis and conjunctivitis [3]. Because of the
bothersome side effects (sedation, impaired cognitive
and psychomotor functions) of the first marketed med-
ications, second generation H1A have been developed
and approved over the last 25 years. They exhibit a low
sedating potential related to their poor ability to cross
the blood–brain barrier. They are recommended as
first choice medications for allergic rhinitis and con-
junctivitis [4,5]. Up to date, 9 second generation H1A
are available in France in various formulations. All
have evidenced their efficacy and safety in randomizedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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from studies in real-life conditions. Although most pa-
tients report being relieved by medication, one out of
five remains unsatisfied, as shown by a self-completion
survey conducted among European patients [6].
The present study was designed to examine, in current
practice, the main reasons why physicians decide to change
their patients’ treatment and identify the main criteria de-
termining the choice of a second generation oral H1A. In
addition, patient evaluation and satisfaction was assessed
during the first month after treatment switch or initiation,
in order to gather data on efficacy and tolerance in field
conditions. Finally, the analysis attempted to describe the
profile of patients who best responded to treatment.Methods
Study design and setting
The study was a longitudinal, prospective, multicenter
survey conducted in mainland France. Data collection
did not interfere with patients’ medical care or with any
of the physicians’ decisions. In accordance with French
law, formal approval from an ethics committee is not
required for observational studies. Before inclusion, the
purpose and objectives of the study were explained to
patients and written informed consent was obtained. All
procedures were performed in accordance with the
ethical principles of the Helsinki declaration, with
Good Epidemiological Practice guidelines and with the
national regulations in force. The French “Commission
Nationale Informatique et Libertés”, an independent
administrative body that operates in accordance with the
data protection legislation, gave its approval for the study.
Data were collected and managed anonymously.Participants
All French allergy specialists (i.e. 1,250 physicians) were
invited to take part in the survey by mail. Assuming that
20% would accept, and 85% of them could actually in-
clude patients, the final pool was expected to include
215 physicians. Following their inclusion, the retained
practitioners were to propose the survey to 10 consecutive
patients meeting the inclusion criteria: (i) adult outpatient;
(ii) diagnosed with allergic rhinitis, either intermittent or
persistent (according to ARIA classification [7]), associated
or not with allergic conjunctivitis, with no or mild and con-
trolled asthma (according to GINA classification [8]); (iii)
presenting with symptoms that require a second generation
oral H1A in monotherapy, depending on the physician’s
decision. It could be a treatment initiation, if no previ-
ous H1A therapy had been given or a switch from a pre-
vious H1A treatment, either first or second generation.
Patients receiving any other treatment for allergic rhinitis
(such as allergen immunotherapy) were excluded from thesurvey, as were pregnant or lactating women, or patients
unable to answer auto-questionnaires.
Data collection
Three different questionnaires were used during the survey.
The first one (physician questionnaire) was filled in by the
physician on the day of inclusion (D0) and contained items
on socio-demographic characteristics, medical history of pa-
tients, previous treatment, new treatment chosen on the day
of inclusion and the motivations for this choice. The second
questionnaire (quality of life (QOL) auto-questionnaire),
filled in on D0 and D30, focused on the description of
symptoms and disorders related to allergic rhinitis and
its treatments. Questions about satisfaction, perception
of efficacy and tolerance of the second generation H1A
were added to this questionnaire filled in on D30.
Thirdly, a daily auto-questionnaire was filled in by the
patient at home during the first 10 days of the new
treatment (i.e. from D1 to D10). It assessed patient’s
daily global, nasal and ocular symptoms (see below).
On D10 (or on the last day of treatment, in the event of
premature termination), questions about satisfaction, per-
ception of efficacy and tolerance of the treatment were
also added. Patients returned the auto-questionnaires by
mail to the survey monitor at the end of follow-up.
Objectives and outcomes
The primary assessment criterion was the main reason
cited by physician for choosing a second generation oral
H1A, as reported at inclusion (D0). Each choice was de-
scribed for the whole cohort of subjects, or by sub-
groups, according to prior therapy, associated diagnosis
of conjunctivitis or not, and the periodicity of symptoms
(persistent or intermittent). The physician was asked to
rank the three main reasons in a list: efficacy, rapidity of
onset of action, length of action, global tolerance, cardiac
safety, absence of sedative effect, absence of fatigue, absence
of mouth dryness, pharmacokinetic characteristics, safety
for at-risk patients, convenience of formulation. The main
reason cited by the practitioner for giving up the previous
treatment was also described (choices were: not convenient
for at-risk patients, non-convenient formulation, insuffi-
cient efficacy, drug interaction issue, tolerance issue).
The secondary objectives were to assess the efficacy
and tolerance of the newly prescribed second generation
H1A in real-life conditions, and to characterize the
profile of patients who best responded to this treatment.
Alleviation of the main symptoms was reported in the
10-day auto-questionnaire. Patients rated daily three
nasal symptoms (sneezing, congestion, rhinorrhea) and
three ocular symptoms (itching eyes, painful eyes, tear-
ing eyes) on a 4-point Likert scale graduated 0 = “no
symptoms”; 1 = “mild and not troublesome symptoms”;
2 = “moderate, troublesome, but tolerable symptoms”;
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A nasal score, an ocular score and a global symptom
score were calculated each day as the sum of scores for
the nasal symptoms, ocular symptoms, and all symptoms,
respectively. Times to nasal recovery, ocular recovery and
global recovery were determined when the nasal score,
ocular score and global symptom score reached zero,
respectively. A patient was considered as responding to
treatment when the symptom score was reduced by 50%
when compared to baseline, i.e. symptom score obtained
at D1 before taking the first tablet of the new treatment
(nasal, ocular and global response were characterized).
The rate of responders was calculated daily between D2
and D10. A patient was classified as an early responder
when he/she responded before the mean time to response
of the whole cohort; as a late responder if he/she responded
later; or as a non-responder if he/she did not respond until
the 10th day of treatment.
Patient satisfaction (rated on a 4-point Likert scale
graduated from 0 = “not satisfied” until 3 = “very satisfied”)
was described at D10 and D30, in the whole cohort and
by previous treatment subgroups. Similarly, patients were
also asked at D10 and D30 whether the new treatment
was more effective, as effective, or less effective than the
previous treatment to relieve their symptoms, whether it
was better tolerated, equally well tolerated, or less well
tolerated, and whether it was more rapid, as rapid, or
less rapid to relieve their symptoms. Relief of disorders
occurring during daily activities was assessed by the patient
in the daily auto-questionnaire (from D1 to D10) using a
numeric scale (0 = “no relief” until 10 = “total relief”). The
effects of the new treatment on QOL (assessed by the
Mini-RQLQ score [9] and a visual analog scale for global
impact) and on daytime sleepiness (Epworth visual analog
scale [10]) were described by the patient at D0 and D30.
Furthermore, the cumulative distribution frequency of
scores for mini-RQLQ was analyzed. The minimal clin-
ically important difference (MCID) was set at 0.7 points,
in accordance with recently published data [11].
The safety and tolerability were assessed by the occur-
rence of adverse events (AEs) throughout follow-up.
Statistical methods
Patient characteristics were described for the whole cohort.
Quantitative and qualitative variables were analyzed using
usual descriptive statistics. The differences between
groups of patients (rhinitis alone versus rhinoconjunctivitis;
persistent versus intermittent disease) were explored
through univariate and multivariate logistic regressions,
entering sex, previous treatment, severity of the disease
(according to ARIA classification [7]), time from allergic
rhinitis onset, occurrence of asthma, occurrence of other al-
lergies, familial history of allergy and response to treatment
as explicative variables. Post-hoc analysis was performed tocharacterize the profile of responders (early versus late
versus no response), through univariate and stepwise
multivariate logistic regressions, entering the same var-
iables plus occurrence of conjunctivitis and periodicity
of disease. Univariate analyses were based on the Chi-2
test, and were entered in the stepwise model with a p value
threshold of 0.35, then retained as significant for a 2-sided
p value ≤ 0.05. Evolutions of numeric scores or visual
analog scales throughout treatment were compared by
the 2-sided Student T-test for matched measures.
The criterion of the primary objective (main reason
for choosing the new second generation H1A) was re-
ported with frequency and 95% confidence interval for
the whole cohort, then for subgroups according to the
occurrence of conjunctivitis (rhinitis alone versus rhi-
noconjunctivitis), and to the periodicity of the disease
(persistent versus intermittent). Chi-2 test was used for
comparing subgroups.
Data management and statistical analyses were per-
formed using SAS 9.2 software.Sample size
Assuming that the adverse effects associated with first
generation H1A treatment would prevail in about 30%
of patients [12], that “good tolerance” was likely to be
the most cited reason for choosing a second generation
H1A, and assuming a standard deviation of 8%, taking a
two-sided alpha risk of 5% and a rate of non-analyzable
cases of 5%, 2,000 patients were required.Results
Patients
Overall, 237 French allergy specialists participated in the
study and included 1,080 patients between March 2011 and
October 2012. Socio-demographic and medical characteris-
tics of the patients are presented in Table 1.
As shown by univariate analyses (Table 2), persistent
rhinitis was more frequently associated with familial
history of allergy, moderate to severe symptoms and
asthma, whereas intermittent rhinitis was more frequently
associated with conjunctivitis. According to multivariate
analysis, the risk of a patient having asthma was 2.0 fold
higher (95% confidence interval [1.2-3.3], p = 0.0069) if
he/she experienced a persistent form of rhinitis, and the risk
of having conjunctivitis symptoms was 1.8 fold higher (95%
confidence interval [1.1-2.9], p = 0.0146) with the intermit-
tent form. Other characteristics (sex, time from onset of
allergy) were not significantly different between groups.
Similarly, patients suffering from rhinoconjunctivitis were
more likely to exhibit moderate to severe symptoms than
those with rhinitis alone (83.8% versus 77.6%; p = 0.03).
Other characteristics were not significantly different
between groups.
Table 1 Socio-demographic and medical characteristics of
the cohort
Number of patients included 1,080
Age* (n = 1080) 34.7 ± 12.7 years
Sex (n = 1046)
Male 41.1%
Female 58.9%






Time from allergic rhinitis onset* (n = 1034) 9.8 ± 9.7 years
Familial history of allergy (n = 1065) 56.4%
Periodicity of allergic rhinitis (n = 995)
Persistent 63.2%
Intermittent 36.8%
Severity of symptoms (ARIA) (n = 884)
Mild 18.0%
Moderate to severe 82.0%
Concomitant disease
Conjunctivitis (n = 1070) 70.9%
Asthma (n = 1064) 26.0%
Other allergies (n = 1072) 16.6%
Atopic eczema (n = 1064) 6.4%
Sinusitis (n = 1064) 7.8%
Urticaria (n = 1064) 9.5%





Regular contact with pet (n = 1048) 44.4%
*mean ± SD.







Frequency (n = 995) 36.5% 63.6%
Familial history of allergy (n = 982) 55.4% 57.0% 0.652
Severity of symptoms (ARIA) (n = 837) <0.001
Mild 24.8% 13.6%
Moderate to severe 75.2% 86.4%
Concomitant disease
Conjunctivitis (n = 988) 74.5% 67.8% 0.0258
Asthma (n = 984) 22.2% 27.9% 0.0463
*2-sided Chi-2 test.
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for their allergic rhinitis during the 24 months preceding
inclusion. From the 87.8% who had been treated, 55.6%
were insufficiently relieved by the treatments adminis-
tered during the previous 24 months, as reported at in-
clusion by the physician. Among patients suffering from
rhinoconjunctivitis, 73.7% took a specific treatment and
52.3% were insufficiently relieved. The therapeutic class
of treatments administered in the previous 24 months
were oral H1A (88.0% of patients), local H1A (12.5%), local
corticosteroids (33.6%), cromones (8.7%) and leukotriene
antagonists (6.8%).Reasons for treatment choice
On the day of inclusion, physicians prescribed a second
generation oral H1A in monotherapy. The main molecule
was bilastine (89.9% of cases), followed by ebastine (4.8%)
and desloratadine (1.9%). The reasons cited to opt for this
new treatment are shown in Figure 1. The most frequently
cited reason was the expected efficacy, which was reported
in 90.7% of cases (85.3% as the main reason).
Physicians also justified why they chose to stop the previ-
ous treatment. “Lack of efficacy” was the most cited reason
(78.2% overall; 90.9% for ebastine; 88.0% for desloratadine),
followed by “tolerance issue” (16.1% overall; 29.2% for
mizolastine; 22.4% for levocetirizine; 21.9% for cetirizine).
Efficacy and tolerance of the second generation
H1-antihistamine
Symptoms were assessed daily during the 10 first days of
treatment using a 4-point Likert scale. At D10, 719 out
of 1,080 (i.e. 66.6%) returned the auto-questionnaire.
Evolution of each symptom throughout time was very
favorable, as shown in Figure 2 for nasal and ocular
symptoms. Mean nasal and ocular symptom scores are
shown in Figure 3.
At D30, at the end of follow-up, 685 out of 1,080
(i.e. 63.4%) returned the auto-questionnaire. Among
them, 67.9% of patients considered that the new H1A
was more effective than the previous treatment to relieve
symptoms of allergic rhinitis; 26.2% as effective; and 5.9%
less effective. They reported being very satisfied (47.2%) or
satisfied (49%) with the new treatment. The satisfaction
rate was higher (although no statistical test was per-
formed) for patients who were switched from a previous
treatment (87.5% satisfied or very satisfied), compared to
the patients treated for the first time (78.8%). Patients who
reported being satisfied had a mean improvement in nasal
and ocular scores and in global mini-RQLQ score of 2.9,
2.4 and 1.4 points, respectively. Patients who were very
satisfied with their treatment had mean score changes of
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All citations Citation in first choice
Figure 1 Reasons cited by physicians for selecting a second generation oral anti-H1.
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scores and global mini-RQLQ score, respectively.
Patient QOL evolved favorably throughout follow-up, as
assessed by the significant reduction in mini-RQLQ scores
(global scores and sub-scores), measure of global impact
using a visual analog scale and Epworth scale, between
































































































Figure 2 Evolution of nasal and ocular symptoms between D1 and D
2 = “moderate, troublesome, but tolerable symptoms”; 3 = “severe, badly toMCID of −0.7 points for mini-RQLQ [11]), and a
distribution-based MCID of −1 point (i.e. half of standard
deviation at baseline [11]) for the visual analog scale, a
large majority of patients evidenced such improvements
during treatment, as shown in Table 3. Ratios were similar
whether patients had rhinitis alone or rhinoconjunctivitis,










































































10. 0 = “no symptoms”; 1 = “mild and not troublesome symptoms”;






























Figure 3 Mean scores of nasal and ocular symptoms between
D1 and D10.
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(6.1%) during follow-up: sleepiness, fatigue, dry mouth,
headache, cardiac disorders, etc. These AEs were reported
by patients as the reason for premature withdrawal of treat-
ment. At D30, 2.5% of patients declared that their tolerance
towards the new H1A was worse than towards their previ-
ous treatment, versus 42.2% who declared it was better and
54.9% who reported that tolerance was the same.
Response to treatment
The mean time to global recovery ± SD (i.e. to total relief
of symptoms) was 6.6 days ± 3.7 (median time = 6 days).
During the 10 days of treatment, the rate of responders
















Global Nose Eyes Activity Othe
Mini RQLQ score
Figure 4 Evolution of QOL and daytime sleepiness between D0 and Dlevel, as detailed in Methods) was 86.1%. Consequently,
13.9% of patients were considered as non-responders
to treatment. The responders were distributed into
early responders (78.2%) and late responders (7.9%),
whether the response occurred before (and including)
D6 or after D6.
The course of symptom relief differed between patients
suffering from rhinitis alone and those diagnosed with
rhinoconjunctivitis, as shown in Figure 5. In the event
of associated conjunctivitis, the rate of global response
was significantly higher during the early days of treatment
than for rhinitis alone (D2 and D3: p ≤ 0.02). The differ-
ence was mainly nasal symptoms, which were significantly
more persistent until D6 in the event of rhinoconjunctivitis
(p ≤ 0.004). Meanwhile, the frequency of ocular symptoms
relief was similar between groups, but higher than 35% from
D2, and reaching 90% at D10. Otherwise, there was no dif-
ference in the course of response (global, nasal and ocular)
between patients with intermittent or persistent rhinitis
(not shown).
According to the multivariate analysis, one factor emerged
as predictive of the global response to treatment. Indeed,
a patient reporting a food allergy was 4.7 fold at risk of
being a late responder than a patient with no food al-
lergy (p = 0.045). All other variables entered in the model
(sex, time from the onset of rhinitis, occurrence of
asthma, occurrence of conjunctivitis, periodicity of rhinitis
(intermittent or persistent), previous treatment, familial
history of allergy ) failed to explain the variability of the
response to treatment. It should be noted that the sever-
ity of asthma (as graded in the GINA classification) was
excluded from the model, as the rate of missing values






















Table 3 Change in quality of life and daytime sleepiness between D0 and D30
D30 – D0 % of patients achieving MCID*
Mean ± SD (N) Whole cohort Rhinitis alone Rhinoconjunctivitis
Quality of life
Mini-RQLQ score (from 0 to 6)
Global −1.57 ± 1.51 (677) 72% 69% 72%
Nasal −2.12 ± 1.84 (675) 77% 81% 76%
Ocular −1.23 ± 1.76 (673) 56% 16% 73%
Activity −1.65 ± 1.77 (676) 72% 75% 71%
Others −1.43 ± 1.50 (675) 71% 67% 72%
Global impact (visual analog scale from 0 to 10) −2.82 ± 3.12 (649) 65% 73% 62%
Daytime sleepiness
Epworth scale (visual analog scale from 0 to 10) −2.18 ± 5.01 (660)
*MCID: minimal clinically important difference. MCID was set at −0.7 for mini-RQLQ scores and at −1 for quality of life global impact.
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The present survey observed 1,080 patients with allergic
rhinitis treated with second generation H1A by allergy
specialists in current practice. It revealed that the main
reason to opt for this new treatment was its expected
efficacy, while the main reason to interrupt the previous
treatment was poor efficacy.
One of the inclusion criteria specified that patients
would receive second generation oral H1A in monother-
apy, depending on the physician’s decision. According to
ARIA guidelines, only patients with mild symptoms of
allergic rhinitis should have met this criterion. However,
most of the patients had moderate to severe rhinitis.
This observation is in accordance with a cross-sectional
prescription survey conducted in France [13] and con-
firmed that, in real life practice, physicians prescribe
H1A as first line treatment.
In this cohort, the main compound chosen by practi-
tioners was bilastine. Some patient characteristics dif-


























































Figure 5 Rate of responders between D2 and D10.designed to assess the efficacy or safety of bilastine.
Firstly, the current study included patients with intermit-
tent and persistent allergic rhinitis or rhinoconjunctivitis
(according to ARIA classification [5]), whereas clinical
trials selectively included patients with seasonal [14,15]
or perennial [16] allergic rhinitis only. Secondly, 18% of
patients in this observational study exhibited mild symp-
toms of allergic rhinitis, while clinical trials included
patients with moderate to severe symptoms only [14-16].
Thirdly, the measures of efficacy and the assessment times
were not identical to those used in clinical trials. Indeed,
nasal and ocular symptom scores were simplified in the
current study, as compared to those used in clinical trials
[14-16], due to the study design, which was observational
and based solely on patient assessment during follow-up.
Here, several efficacy indicators were employed: symptom
score rating, quality of life rating on Likert scales and vis-
ual analog scales, relevant outside randomized clinical tri-
als. If only because of these differences, the data from
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scores were comparable to those of some clinical trials
[15,17]. To improve the analysis, the rate of patients
reaching the MCID for quality of life scores was deter-
mined, according to methods employed by the US Agency
for Healthcare Research and Quality [11]. It revealed
that a majority of patients achieved MCID during
follow-up, reinforcing the role of H1A in allergic rhinitis/
rhinoconjunctivitis sufferers.
Whereas the estimated number of subjects required
was 2,000, only 1,080 with usable data were finally included
in the study. Indeed, the number of required patients
had been overestimated. However, the sample size was
large enough to allow descriptive analysis of the primary
objective. In fact, the hypothesis chosen to estimate sample
size (i.e. tolerance was likely to be the main reason cited
to opt for a second generation H1A) was not verified.
Conversely to what was assumed, the main reason for
choosing a second generation H1A was its expected effi-
cacy. This reason was far more cited than tolerance or
the rapidity of action of the new compound. These data
suggest that physicians consider second generation H1A
as very safe, the differentiating property being efficacy.
In line with this assumption, the incidence of treatment
emergent adverse events for bilastine or desloratadine,
measured in double-blind randomized clinical trials, was
not different from that of placebo [15].
The present survey confirmed that second generation
oral H1A are effective in relieving nasal and ocular
symptoms in real-life conditions. The time course of
the effect was quite rapid, as recovery was obtained by
6 to 7 days on average. Furthermore, symptoms were
greatly reduced within the first days of treatment for
most patients. Response to treatment was particularly
rapid in the subgroup of patients with conjunctivitis
associated with allergic rhinitis, compared to those
with rhinitis alone, particularly when nasal response
was examined. The response with regard to ocular
symptoms was higher than that for nasal symptoms,
throughout the 10-day treatment course and regardless
of whether or not conjunctivitis was associated with
rhinitis. On the contrary, the periodicity of the disease
(persistent or intermittent) did not modify response
kinetics. Evolution was comparable to that seen in ran-
domized clinical trials [14,15]. However, due to the
non comparative design of the study, we could not rule
out whether symptom relief under treatment was greater
than under placebo or in the absence of treatment. It
should also be noted that about 33% of patients who were
included and answered the first questionnaire during the
medical consultation did not comply when they returned
home and did not return the 10-day auto-questionnaire.
However, those who did accept were fairly compliant to
survey requests, as the rate of missing data was only around10%. In addition, only 3% of patients were then lost to
follow-up between D10 and D30. The rate of patients
lost to follow-up did not impact the assessment of the
main objective, but may have generated a bias in the
analysis of response to treatment, as it cannot be excluded
that patients who did not return the auto-questionnaire
were poorly satisfied with the treatment. Conversely, it
can be assumed that those patients who were rapidly re-
lieved from allergic rhinitis symptoms were poorly moti-
vated to complete the questionnaire. We are unable to
discriminate between these two hypotheses. However, the
profile of lost to follow-up patients was similar at baseline
to that of the whole cohort (not shown).
The definition of responders was based on a 50% re-
duction in symptom intensity. This choice seemed
relevant from a clinical view point, as the threshold
was largely higher than a potential placebo effect,
which has been estimated to be around 27% [18]. In
accordance to the evolution of symptoms, nearly all
patients who responded to treatment were classified
as early responders. The analyses did not highlight any
patient characteristic that could influence the response to
treatment, except the occurrence of a food allergy, which
was the most frequent concomitant allergy reported by
patients. Associated food allergies may well represent a
marker of a more severe atopic background, as shown
in one study of asthma phenotype in children [19]. The
multivariate regression model also showed that patients
with controlled asthma were more likely to be late re-
sponders than patients without asthma. However, this trend
was not statistically significant (OR = 1.9; p = 0.07).
Although they were diagnosed with rhinitis alone by the
allergy specialist during the inclusion visit, 47.7% of patients
reported ocular symptoms in their auto-questionnaire
at D0. However, the mean score for ocular discomfort
assessed by patients on the 10-point Likert scale was 2.8
in the “rhinitis alone” group, compared to 6.4 in the
“rhinoconjunctivitis” group. It is likely that there was a
gap between the diagnosis of conjunctivitis by physicians
and the perception of ocular symptoms by patients. Con-
sequently, it may be questionable whether comparisons
between “rhinitis alone” and “rhinoconjunctivitis” groups
on the basis of doctors’ assessments are relevant. However,
a significant difference was noted at baseline regarding the
impact of the disease on quality of life.
Although many patients responded to the 10-day treat-
ment with second generation H1A in the studied cohort, a
minority (about 14%) were classified as non-responders.
Non-compliance can partially account for the lack of effi-
cacy, as described by others [20]. However, this parameter
was hardly recordable in an observational study. Treat-
ment failure for H1A has also been reported to be more
frequent in children when allergic rhinitis is caused by
house dust mites, compared to pollens, i.e. in the event of
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current study, however, the periodicity of rhinitis was not
associated with the response rate.
Overall, between 8 and 9 patients out of 10 declared
being satisfied with their second generation oral H1A,
which significantly improved their quality of life during
treatment. This ratio is high, compared to the 60% of
dissatisfied allergic rhinitis patients seeking another
medication to improve their health [22].
Competing interest
Pascal Demoly received fees from Pierre Fabre Medicament France to design
and coordinate the study and to analyze the results. He is also a consultant
and a speaker for Stallergenes, ALK, Circassia and Chiesi and was a speaker
for Merck, Astra Zeneca, Menarini and GlaxoSmithKline. Anca M. Chiriac has
no conflict of interest. Benoît Berge is employed by Euraxi Pharma. Michel
Rostin is employed by Pierre Fabre Médicament France.
Authors’ contributions
PD was the medical expert involved in designing the study protocol,
coordinating the study and analyzing the results. AMC contributed to data
analysis and manuscript writing. BB carried out data management and
statistical analysis. MR coordinated the study organization. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank Odile Capronnier who provided medical writing services.
Funding
The survey was performed thanks to an unrestricted grant from Pierre Fabre
Médicament France (sponsor). Euraxi Pharma was the Contract Research
Organization appointed by the sponsor to organize the survey, from
recruitment of investigators to data analysis. Marketing or commercial
representatives of the sponsor were not involved in the recruitment of
investigators, in accordance with French legislation. In the frame of this non
interventional study, prescribed second generation H1A were not provided
free to patients. In France, these drugs are dispensed only under physician’s
prescription; 30% is reimbursed by French Public Health Insurance. Physicians
had no inducements to prescribe any drug.
Author details
1Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve,
University Hospital of Montpellier, France; and Sorbonne Universités, UPMC
Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France. 2EURAXI
PHARMA, 10 rue Gutenberg, BP 80325, 37303 Joué-les-Tours, France. 3Medical
Affairs Department, Pierre Fabre Médicament, 81106 Castres Cedex, France.
Received: 4 April 2014 Accepted: 20 May 2014
Published: 6 June 2014
References
1. Klossek JM, Annesi-Maesano I, Pribil C, Didier A: [INSTANT: national survey
of allergic rhinitis in a French adult population based-sample]. Presse Med
2009, 38(9):1220–1229.
2. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC: A survey of
the burden of allergic rhinitis in Europe. Allergy 2007, 62(Suppl 85):17–25.
3. Ramirez LF, Urbinelli R, Allaert FA, Demoly P: Combining H1-antihistamines
and nasal corticosteroids to treat allergic rhinitis in general practice.
Allergy 2011, 66(11):1501–1502.
4. Simons FE, Simons KJ: H1 antihistamines: current status and future
directions. World Allergy Organ J 2008, 1(9):145–155.
5. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE,
Bachert C, Bonini S, Boulet LP, Bousquet PJ, Brozek JL, Canonica GW, Casale
TB, Cruz AA, Fokkens WJ, Fonseca JA, van Wijk RG, Grouse L, Haahtela T,
Khaltaev N, Kuna P, Lockey RF, Lodrup Carlsen KC, Mullol J, Naclerio R,
O'Hehir RE, Ohta K, Palkonen S, Papadopoulos NG, Passalacqua G, Pawankar R,
et al: Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in
10 years and future needs. J Allergy Clin Immunol 2012, 130(5):1049–1062.6. Valovirta E, Myrseth SE, Palkonen S: The voice of the patients: allergic
rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol 2008, 8(1):1–9.
7. Demoly P, Allaert FA, Lecasble M, Bousquet J: Validation of the
classification of ARIA (allergic rhinitis and its impact on asthma). Allergy
2003, 58(7):672–675.
8. GINA: Global Strategy for Asthma Management and Prevention 2012 (update).
Global Initiative for Asthma; 2012. http://www.ginasthma.org/, viewed on
06/16/2014.
9. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN: Development and
validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.
Clin Exp Allergy 2000, 30(1):132–140.
10. Johns MW: A new method for measuring daytime sleepiness: the
Epworth sleepiness scale. Sleep 1991, 14(6):540–545.
11. Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D, Aronson N:
Treatments for Seasonal Allergic Rhinitis. Rockville (MD): Agency for
Healthcare Research and Quality (US); 2013.
12. Falliers CJ, Brandon ML, Buchman E, Connell JT, Dockhorn R, Leese PT, Miller
J, Wasserman SI, Zeterberg JM, Altman R, Love S, Samuels LL: Double-blind
comparison of cetirizine and placebo in the treatment of seasonal
rhinitis. Ann Allergy 1991, 66(3):257–262.
13. Demoly P, Concas V, Urbinelli R, Allaert FA: Spreading and impact of the
World Health Organization's Allergic Rhinitis and its impact on asthma
guidelines in everyday medical practice in France. Ernani survey. Clin Exp
Allergy 2008, 38(11):1803–1807.
14. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L,
Roger A, Sologuren A, Valiente R: Efficacy and safety of bilastine 20 mg
compared with cetirizine 10 mg and placebo for the symptomatic
treatment of seasonal allergic rhinitis: a randomized, double-blind,
parallel-group study. Clin Exp Allergy 2009, 39(9):1338–1347.
15. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de
Heyning P, Loureiro A: Comparison of the efficacy and safety of bilastine
20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy
2009, 64(1):158–165.
16. Sastre J, Mullol J, Valero A, Valiente R: Efficacy and safety of bilastine
20 mg compared with cetirizine 10 mg and placebo in the treatment of
perennial allergic rhinitis. Curr Med Res Opin 2012, 28(1):121–130.
17. Noonan MJ, Raphael GD, Nayak A, Greos L, Olufade AO, Leidy NK, Champan
D, Kramer B: The health-related quality of life effects of once-daily cetiri-
zine HCl in patients with seasonal allergic rhinitis: a randomized double-
blind, placebo-controlled trial. Clin Exp Allergy 2003, 33(3):351–358.
18. Demoly P, Didier A, Blay F, Vervloet D, Devillier P: Taille de l’effet
thérapeutique dans les essais cliniques de la rhinite allergique
saisonnière. Revue Francaise D Allergologie 2011, 51(2):84–94.
19. Just J, Gouvis-Echraghi R, Rouve S, Wanin S, Moreau D, Annesi-Maesano I:
Two novel, severe asthma phenotypes identified during childhood using
a clustering approach. Eur Respir J 2012, 40(1):55–60.
20. Koberlein J, Kothe AC, Schaffert C: Determinants of patient compliance in
allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol 2011, 11(3):192–199.
21. Turner PJ, Kemp AS: Allergic rhinitis in children. J Paediatr Child Health
2012, 48(4):302–310.
22. Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH, Lanier
BQ, Penna P: Keys to successful management of patients with allergic
rhinitis: focus on patient confidence, compliance, and satisfaction.
Otolaryngol Head Neck Surg 2007, 136(6 Suppl):S107–S124.
doi:10.1186/1710-1492-10-29
Cite this article as: Demoly et al.: Reasons for prescribing second
generation antihistamines to treat allergic rhinitis in real-life conditions
and patient response. Allergy, Asthma & Clinical Immunology 2014 10:29.
